The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- FDA Budget Request Calls For 8% Increase Over FY14: User Fees Make Up Over 90% of New Funds Mar. 07, 2014
- Medicare To Provide Free Hep C Screening For Baby Boomers (1945-1965) Under Proposed Policy; Timely Boost For Rx Mar. 05, 2014
- Obama FY15 Budget Proposal Includes Accelerated Donut Hole Closure, Part D Rebates, Other Repeats From FY14 Mar. 05, 2014
See More Research Notes